Literature DB >> 16163540

The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1alpha in mice.

Barbara A E de Koning1, Dicky J Lindenbergh-Kortleve, Rob Pieters, Edmond H H M Rings, Hans A Büller, Ingrid B Renes, Alexandra W C Einerhand.   

Abstract

Chemotherapy-induced intestinal damage is a very important dose-limiting side effect for which there is no definitive prophylaxis or treatment. This is in part due to the lack of understanding of its pathophysiology and impact on intestinal differentiation. The objective of this study was to investigate the gene expression of the small intestinal transcription factors HNF-1alpha, Cdx2, GATA-4 in an experimental model of methotrexate (MTX)-induced intestinal damage, and to correlate these alterations with histological damage, epithelial proliferation and differentiation. HNF-1alpha, Cdx2 and GATA-4 are critical transcription factors in epithelial differentiation, and in combination they act as promoting factors of the sucrase-isomaltase (SI) gene, an enterocyte-specific differentiation marker which is distinctly downregulated after MTX treatment. Mice received two doses of MTX i.v. on two consecutive days and were sacrificed 1, 3 and 7 or 9 days after final injection. Segments of the jejunum were taken for morphological, immunohistochemical and quantitative analyses. Intestinal damage was most severe at day 3 and was associated with decreased expression of the transcriptional factors HNF-1alpha, Cdx2 and GATA-4, which correlated well with decreased expression of SI, and seemed inversely correlated with enhanced proliferation of epithelial crypt cells. During severe damage, the epithelium was preferentially concerned with proliferation rather than differentiation, most likely in order to restore the small intestinal barrier function rather than maintaining its absorptive function. Since HNF-1alpha, Cdx2 and GATA-4 are critical for intestine-specific gene expression and therefore crucial in epithelial differentiation, these results may explain, at least in part, why intestinal differentiation is compromised during MTX treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16163540     DOI: 10.1007/s00280-005-0119-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

Review 1.  Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.

Authors:  Barbara Vanhoecke; Emma Bateman; Bronwen Mayo; Eline Vanlancker; Andrea Stringer; Daniel Thorpe; Dorothy Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

2.  Continuous enteral administration can overcome the limited capacity to absorb glucose in rats with methotrexate-induced gastrointestinal mucositis.

Authors:  Margot Fijlstra; Edmond H H M Rings; Theo H van Dijk; Torsten Plösch; Henkjan J Verkade; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2012-09-26       Impact factor: 3.603

3.  Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model.

Authors:  Margot Fijlstra; Mithila Ferdous; Anne M Koning; Edmond H H M Rings; Hermie J M Harmsen; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2014-11-08       Impact factor: 3.603

4.  Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.

Authors:  A K Sinha; S Anand; B J Ortel; Y Chang; Z Mai; T Hasan; E V Maytin
Journal:  Br J Cancer       Date:  2006-07-25       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.